Mannitol B. Braun (Mannitol)

Mannitol functions as an osmotic agent. When infused, it raises plasma osmolality, drawing water out of brain and eye tissues into the bloodstream. This fluid shift reduces tissue swelling, thereby decreasing intracranial and intraocular pressures while also increasing urine output through osmotic diuresis.

The specific dose and infusion rate of Mannitol B. Braun are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and response to therapy. Dosing is individualized and should follow the prescriber’s order and institutional protocols.

Mannitol is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; the decision should be made by the healthcare provider considering maternal and infant health.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both Mannitol and hypertonic saline create an osmotic gradient to reduce cerebral edema, but Mannitol is a sugar alcohol that is filtered by the kidneys, leading to diuresis, whereas hypertonic saline primarily expands intravascular volume and may be preferred when fluid balance is a concern. Choice depends on patient-specific factors and clinician judgment.

Mannitol B. Braun should be stored at 2‑8 °C (refrigerated). Keep the solution in its original container, protect it from light, and avoid freezing or shaking the vial. Do not use the product if the solution appears cloudy or contains particles.

Mannitol B. Braun is given as an intravenous infusion. The solution is typically diluted in compatible IV fluids and administered over a period determined by the prescriber, often ranging from a rapid bolus to a slower infusion, depending on the clinical indication and patient tolerance.

Serious risks include acute renal failure, severe electrolyte disturbances (especially hypernatremia), pulmonary edema from fluid overload, and rare anaphylactic reactions. Patients should be closely monitored for changes in renal function, serum electrolytes, and respiratory status throughout treatment.

Mannitol is contraindicated in patients with known hypersensitivity to mannitol, severe dehydration, active intracranial hemorrhage where rapid volume shifts could worsen bleeding, and in those with severe renal impairment where excretion is compromised. Clinicians must evaluate each patient’s medical history before initiating therapy.